Metoject (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, reducing the production of tetrahydrofolate needed for DNA synthesis. This limits the proliferation of rapidly dividing cells, such as immune cells involved in inflammation and malignant tumor cells.

The dose of Metoject is individualized by the prescribing clinician based on the specific indication, patient weight, renal function, and treatment response. Only a qualified health professional should determine the appropriate dosing schedule.

Methotrexate is classified as pregnancy category X, meaning it is contraindicated in pregnancy due to a high risk of fetal harm. It is also not recommended for breastfeeding mothers because it can be excreted in breast milk and affect the infant.

To request Metoject, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Compared with biologic agents, methotrexate is a small‑molecule antimetabolite that can be administered subcutaneously and is generally less expensive. It has a well‑characterized safety profile but requires regular monitoring of liver function and blood counts, whereas biologics target specific cytokines and have different monitoring requirements.

Metoject should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. Do not store at room temperature for extended periods.

Metoject is given by subcutaneous injection, typically into the abdomen or thigh. The injection site should be rotated to reduce local irritation. Administration is performed by a healthcare professional or a trained patient following aseptic technique.

Serious risks include severe liver toxicity, pulmonary fibrosis, profound bone‑marrow suppression leading to anemia or infection, and rare but life‑threatening allergic reactions. Patients should be monitored closely for signs of these complications and report any concerning symptoms promptly.

Metoject is contraindicated in pregnant women, nursing mothers, and individuals with known hypersensitivity to methotrexate. It should also be avoided in patients with severe renal or hepatic impairment, uncontrolled infections, or those receiving other folate‑antagonist therapies without appropriate supervision.